43 results about "Skin atrophy" patented technology

The invention describes a method of producing extracts from the seeds of meadowfoam, brassicas and crambe plants. A number of subsidiary processes and steps are shown in order to extract differing fractions of oil. Products produced from the above method are also described including uses and methods of these products which include a variety of skin conditions including eczema, facial eczema, dermatitis, external ulcers, welts, rashes, insect bites, allergic reactions and other irritations, burns, wounds, psoriasis, acneiform eruptions, dryness, dry skin, irritation, skin atrophy, secondary infections and the like. The extracts are also described as being a useful compound for treatment of the symptoms of such skin conditions as described above. In particular the use and extraction of glucosinolate (GSL), thiocyanates (TCL) and isothiocyanates (ITCL) is described.

The invention provides human umbilical cord mesenchymal stem cell exosome type external cream and a preparation method thereof, and aims at the solving the problem in effectively inducing human umbilical cord mesenchymal stem cells to massively synthesize and secrete mesenchymal stem cell exosome capable of specifically promoting epidermis cell and hypodermal cell to proliferate, divide and differentiate, promoting the formation of collagenous fibers, reticular fibers and elastic fibers, and adjusting the secreting functions of collagen and mucopolysaccharide. The cream comprises human umbilical cord mesenchymal stem cell exosome extracting liquid and a base cream formula based on the mass ratio ranging from (1:20) to (3:10), wherein the human umbilical cord mesenchymal stem cell exosome extracting liquid is prepared by performing hungry culture on P2-P5 generations of human umbilical cord mesenchymal stem cells and stimulating through epidermal growth factors. The prepared cream has the effects of improving the skin quality, resisting the aging of skin cells, recovering the normal structure and physiological function of the skin, reducing the skin atrophy exsiccosis, and moisturizing the skin tissue.

The invention describes a method of producing extracts from the seeds of meadowfoam, brassicas and crambe plants. A number of subsidiary processes and steps are shown in order to extract differing fractions of oil. Products produced from the above method are also described including uses and methods of these products which include a variety of skin conditions including eczema, facial eczema, dermatitis, external ulcers, welts, rashes, insect bites, allergic reactions and other irritations, burns, wounds, psoriasis, acneiform eruptions, dryness, dry skin, irritation, skin atrophy, secondary infections and the like. The extracts are also described as being a useful compound for treatment of the symptoms of such skin conditions as described above. In particular the use and extraction of glucosinolate (GSL), thiocyanates (TCL) and isothiocyanates (ITCL) is described.

Novel methods for treating or reducing the likelihood of acquiring symptoms or diseases due to the menopause, in postmenopausal women, particularly osteoporosis, vaginal atrophy and dryness, hypogonadism, diminished libido, skin atrophy, connective tissue disease, urinary incontinence, breast, endometrial, ovarian and uterine cancers, hot flashes, loss of muscle mass, insulin resistance, fatigue, loss of energy, aging, physical symptoms of menopause, in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor are disclosed. Said method comprising novel ways of administering and dosing dehydroepiandrosterone (DHEA) in order to take advantage of positive androgenic effects in the vaginal layers lamina propia and / or the layer muscularis, without undesirably causing systemic estrogenic effects in order to avoid the risk of breast and uterine cancer. Pharmaceutical compositions for delivery of active ingredient(s) useful to the invention are also disclosed.

The invention discloses an instant collagen lyophilized ball which comprises the following components in percentage by mass: 14-20% of collagen, 10-15% of trehalose, 10-15% of pullulan, 30-56% of mannitol and 10-20% of sterile injection water. The invention further discloses a preparation method of the instant collagen lyophilized ball. The instant collagen lyophilized ball has the repairing function; the prepared collagen lyophilized ball has very strong hydrophilicity, can be quickly and uniformly dissolved in the use moment, and can be used for reparation and maintenance of skin suffered from medical plastic surgeries of laser, photon, refrigeration, high frequency, grinding, face-lifting and the like; the instant collagen lyophilized ball can be used for treating skin damages, caused by acne or trauma, of depressed scars, couperose skin symptom, skin atrophy, sun burn, heat injury and the like. The instant collagen lyophilized ball prepared according to the method has very strong hydrophilicity, can be uniformly dissolved instantly when in use, is more convenient and fast to use and long in guarantee period, can be stored at the room temperature, and is very convenient to store.

Compositions useful in the treatment of skin atrophy and improvement of skin appearance and texture are disclosed. The methods include the topical administration of vitamin D3 or specific vitamin D3 analogs as an essential ingredient either on its own or in combination with cADPR and or nicotinamide. The compositions are particularly effective in preventing and treating signs of chronological and or photoaging including fine lines, wrinkles and discoloration.

Disclosed are compounds of formula II:wherein A is as defined by the specification. Also disclosed are compositions containing the esters and methods for their use in the regulation of skin atrophy and in the treatment of skin disorders such as dry skin, dandruff, acne and eczema.

This invention relates to a method for inhibition of skin atrophy, or epithelial or mucosal atrophy in women, or to a method for treatment or prevention of symptoms related to said atrophy, said method comprising administering to the woman an effective amount of the compound of formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof.

Disclosed is a non-natural ceramide compound effective for a sphingosine kinase activator, and thus useful for a skin disease treating agent. The sphingosine kinase activator enhances production of sphingosine-1-phosphate to show various physiological activities provided by sphingosine-1-phosphate. The physiological activities include the effects of: controlling multiplication and differentiation of keratinocytes, multiplication of fibroblasts and collagen synthesis, resulting in treatment of wounds, recovery of damaged skin functions in atopic dermatitis and psoriasis; inhibiting wrinkles and skin irritation caused by ultraviolet rays, followed by improvement of wrinkles and inhibition of skin aging; and reducing skin atrophy, which is a typical side effect of local application steroids. Therefore, the sphingosine kinase activator is useful for a skin disease treating agent for treating skin wounds, wrinkles, atopic dermatitis, eczema, psoriasis, or skin atrophy caused by side effects of local application steroids.

Novel compositions comprising one or more of an acid protease and an acidic buffer, the acidic buffer comprising an acid and a pharmaceutically or cosmetically acceptable carrier, vehicle or excipient, useful for treating or preventing abnormal biological conditions, diseases or disorders, and / or for improving the texture or appearance of the skin, and / or for enhancing epidermal exfoliation and / or for enhancing epidermal cell renewal and to methods for the use of the compositions. The acid protease comprises one or more proteolytic enzymes which exhibit proteolytic activity at pH values below that of the surface of the skin, i.e., approximately pH 5.5. The acidic buffer comprises at least one acidic buffering component that can reversibly disassociate hydrogen ions and has buffering capacity at pH values below that of the surface of the skin, i.e., approximately pH 5.5. or mixtures thereof with a pharmaceutically or cosmetically acceptable carrier, vehicle or excipient. The buffer is capable of reducing the pH of the surface of the skin to less than pH 5.5 and is susceptible to neutralization by normal epidermal processes. Such types of abnormal biological conditions, diseases or disorders include skin atrophy, i.e., the thinning and / or general degradation of the dermis often characterized by a decrease in collagen and / or elastin as well as decreased number, size and doubling potential of fibroblast cells, and other maladies including, but are not limited to dry skin, severe dry skin, dandruff, acne, keratoses, psoriasis, eczema, skin flakiness, pruritus, age spots, lentigines, melasmas, wrinkles, warts, blemished skin, hyperpigmented skin, hyperkeratotic skin, inflammatory dermatoses, age-related skin changes and skin in need of cleansers.

The present invention relates to methods for regulating the condition of mammalian keratinous tissue wherein the methods each comprise the step of topically applying to the keratinous tissue of a mammal needing such treatment, a safe and effective amount of a skin care composition comprising:a) a safe and effective amount of a hexamidine compound selected from the group consisting of hexamidine, its salts, and derivatives;b) a safe and effective amount of one or more skin care active selected from the group consisting of sugar amine, vitamin B3, retinoid, peptide, phytosterol, butylated hydroxytoluene and butylated hydroxyanisole, their derivatives, and combinations thereof; andc) a dermatologically acceptable carrier for the hexamidine and the skin care active.In additional embodiments, the above composition is suitable for preventing, retarding, and / or treating dark under-eye circles, puffy eyes, sagging, sallowness as well as spider vessels and / or red blotchiness of skin, promoting skin desquamation, exfoliation, and / or turnover, regulating and / or reducing pore size appearance, preventing / retarding tanning, regulating oily / shiny appearance, preventing, retarding, and / or treating hyperpigmentation in mammalian skin, preventing, retarding, and / or treating itchiness of mammalian skin, preventing, retarding, and / or treating dryness of skin, preventing, retarding, and / or treating fine lines and wrinkles, preventing, retarding, and / or treating skin atrophy of mammalian skin, softening and / or smoothing lips, hair and nails of a mammal, and preventing, retarding, and / or treating the appearance of cellulite in mammalian skin.

The invention relates to a drug which cures the normal psoriasis and a preparing method thereof. The prescription is that hoptoad skin is counted as one weight unit, 25 to 35 of cynanchum, 7 to 14 ofliquorice, 2-4 of datura flower, 4-5 of outdoor hive, 2-3 of silybin vermilion are weighted. The drug is made by rubbing to powder, dipping, boiled frying, filtering and concentrating, etc. The drug of the invention has the functions of detoxification, insect killing, dampness eliminating and itch stopping, immunity resisting, poison drawing and vitality, thus being suitable for any parts of bodyskin with the available rater of 100 percent and the clinic curing rate of more than 75 percent. The drug of the invention has obvious curative effect for a long time and long time of release, low recurrence rate, not generating stimulation, skin atrophy and coloration and other side effects to the skin.

The invention belongs to the field of medical cosmetology, and particularly relates to a polypeptide composition for rapidly repairing a hormone face and application thereof in cosmetics. The polypeptide composition contains antimicrobial peptide, anti-inflammatory peptide and copper peptide. The polypeptide composition is free of toxic and side effects, and different degrees of skin atrophy, thinning, diffuse flushing, skin erythema, local swelling, acne, folliculitis pustules and the like caused by the hormone face can be effectively repaired; meanwhile, the polypeptide composition can repair damaged skin and restore the skin health state.

The invention relates to hormonal face servicing essence cream and a preparation method therefor. Raw material ingredients of the hormonal face servicing essence cream comprise a mussel extract, schizophyllan, a gentian root extract, coconut oil, an oak root extract, a cork oak bark extract, urea and the like. The hormonal face servicing essence cream disclosed by the invention has the beneficialeffects that the ingredients are natural, and the hormonal face servicing essence cream is moderate and non-irritating; and in case of insisted use, the skin barrier can be enhanced, the defense capability of skin is improved, the physiological repair of the skin is promoted, the immunologic functions of the skin are improved, and thus, the action of repairing hormonal faces is exerted. The hormonal face servicing essence cream can be used for effectively repairing erubescence, edema, red spots, papillae, pustular eruption, dryness desquamation, atrophoderma thinning, angiotelectasis, pigmentation, itching, burning sensation, ache and skin tight sense caused by the hormonal faces and gradually restoring the skin to a health status; and the hormonal face servicing essence cream has a certain repair effect on the hormonal faces of various degrees, is short in repair time and is free of rebound after repair.

A topical composition and the method using the composition, which contains an antifungal agent and a low potency anti-inflammatory steroid which is safe and effective such as desonide or its derivative. The low potency steroid agent does not cause side effects such as skin atrophy, striae and hypopigmentation. The composition can be formulated in a dosage form such as a cream, ointment, gel, lotion, foam, powder, aerosol, spray, shampoo, or liquid solution. The composition can be used to treat a fungal disease such as tinea pedis, tinea capitis, tinea corporis, tinea versicolor, tinea cruris, and candidiasis as well as intertriginous dermatitis complicated by candidiasis.

The present invention is related to a pharmaceutical combination of a glucocorticoid and a Beta-cyclodextrin conjugated vitamin A derivative complex as well as a pharmaceutical composition comprising the same. The combination and the composition of the invention can be used for reducing or eliminating skin atrophy induced by treatment with glucocorticoids (GC). Also comprised is a method for reducing or eliminating skin atrophy induced by GC treatment. Furthermore the invention concerns a kit comprising a glucocorticoid and a Beta-cyclodextrin conjugated vitamin A derivative complex.

Disclosed are topical preparations for inhibiting tyrosine kinase and preparation methods thereof, and especially topical pharmaceutical compositions for inhibiting tyrosine kinase and preparation methods thereof. The active ingredient of the topical preparations is Icotinib or a pharmaceutically acceptable salt thereof. The preparations are suitable for topical application, with minimal skin irritation, no adverse reactions such as pruritus, burning sensations, tingling, dry skin, erythema and rashes, without parahormone-related side effects such as skin atrophy, pigmentation or hypopigmentation for long-term use, as well as no related dermatological symptoms after drug withdrawal. The preparation methods are easily understood, operable, and controllable, and are suitable for industrialization.

A method of producing Klotho protein includes preparing a Klotho plasmid DNA vector, culturing cells, transfecting the cells with the Klotho plasmid DNA vector in a cell culture medium, growing the transfected cells, and harvesting the cell culture supernatant by removing the transfected cells. The Klotho plasmid DNA vector has a mammalian selection marker and a Klotho open reading frame. The cells are primary fibroblast cells and / or mesenchymal stromal cells. A method of manufacturing a cosmetic composition includes combining Klotho protein or the cell culture supernatant with a cosmetically acceptable vehicle. A method of treating a patient to improve the condition and appearance of aging skin includes topically administering the cosmetic composition to the patient. By upregulating the Klotho gene in vitro and incorporating the Klotho protein and growth factors into a composition, transepidermal water loss, skin atrophy, and free radical damage to the skin may be addressed.

In the embodiments, the invention discloses emulsion for elderly people and a preparation method thereof, and belongs to the technical field of daily skin care products. The emulsion for the elderly people comprises the following raw materials in percentage by weight: a humectant, an emollient, an emulsifier, a thickening agent, a neutralizing agent, a skin conditioner, a functional plant extractessence, a chelating agent, a preservative, and pure pine needle juice. The emulsion for the elderly people disclosed by the embodiments of the invention is stable in performance, safe, non-irritating, as well as capable of increasing skin elasticity and making the skin compact; and moreover, the emulsion is capable of achieving the effects of moisturizing, nourishing as well as effectively relieving dryness and sensitivity, thereby fundamentally and comprehensively solving the problems of skin atrophy, dullness and sensitivity, as well as slow metabolism and weak resistance, of the elderly people. Therefore, skin care needs of the elderly people can be met so as to have types of skin care products for the elderly people enriched; and thus, the emulsion for the elderly people has relatively great market potential.

The present invention is related to a pharmaceutical combination of a glucocorticoid and a β-cyclodextrin conjugated vitamin A derivative complex as well as a pharmaceutical composition comprising the same. The combination and the composition of the invention can be used for reducing or eliminating skin atrophy induced by treatment with glucocorticoids (GC). Also comprised is a method for reducing or eliminating skin atrophy induced by GC treatment. Furthermore the invention concerns a kit comprising a glucocorticoid and a β-cyclodextrin conjugated vitamin A derivative complex.

The use, as a dermatological or cosmetic medicament, of compounds capable of transiently interacting with the AhR receptor (aryl hydrocarbon receptor) as agents for modulating skin functions such as sebaceous function, skin healing, skin atrophy termed “dermatoporosis”, estrogen deprivation and defense against infection, without inducing other toxic effects of the TCDD type.The compounds that interact with the AhR receptor are chosen in that they have a metabolism favorable to the dissociation of these effects, in particular by virtue of in situ production from a precursor and / or metabolization modulated in situ.

The invention relates to a drug which cures the normal psoriasis and a preparing method thereof. The prescription is that hoptoad skin is counted as one weight unit, 25 to 35 of cynanchum, 7 to 14 ofliquorice, 2-4 of datura flower, 4-5 of outdoor hive, 2-3 of silybin vermilion are weighted. The drug is made by rubbing to powder, dipping, boiled frying, filtering and concentrating, etc. The drug of the invention has the functions of detoxification, insect killing, dampness eliminating and itch stopping, immunity resisting, poison drawing and vitality, thus being suitable for any parts of bodyskin with the available rater of 100 percent and the clinic curing rate of more than 75 percent. The drug of the invention has obvious curative effect for a long time and long time of release, low recurrence rate, not generating stimulation, skin atrophy and coloration and other side effects to the skin.

The invention belongs to the technical field of Chinese patent medicines, specifically relates to a drug for treating psoriasis, and is mainly used for solving the defects that the existing drug for treating the psoriasis causes atrophoderma and angiotelectasis after being taken for a long time, symptoms are easy to relapse again and the pathogenetic condition relapses after drug withdrawal, and curative effect is bad. The drug for treating psoriasis adopts the following medicines in parts by weight as raw material medicines: 4-5 parts of radix astragali, 1-2 parts of herba schizonepetae, 1-2 parts of ligusticum wallichii, 1-2 parts of Chinese angelica, 2-4 parts of dried rehamnnia roots, 2-4 parts of red peony roots, 2-4 parts of tribulus terrestris, 2-4 parts of polygonum multiflorum, 2-4 parts of cornu bubali, 2-4 parts of galium elegans, 2-4 parts of garter snakes and 1-3 parts of divaricate saposhnikovia roots. The drug for treating psoriasis disclosed by the invention has the advantages of being remarkable in medical effect and capable of treating both symptoms and root causes.

The present invention includes compositions and methods for treating or preventing certain dermal disorders including dermal atrophy, pseudoscars, actinic keratosis, seborrheic or actinic keratoses, lentigines, focal areas of dermal thickening, and coarse wrinkles. In certain embodiments, the compositions useful within the invention comprise a therapeutically effective amount of a mTORC1 inhibitor and a dermatologically acceptable carrier.

This invention relates to a method for inhibition of skin atrophy, or epithelial or mucosal atrophy in women, or to a method for treatment or prevention of symptoms related to atrophy, said method comprising administering to the woman an effective amount of the compound of formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof.